PHARMACEUTICAL COMPANIES

Non-adherence to prescribed medication regimens undermines revenue generation, impacts patient outcomes, affects brand value, and hinders the demonstration of medication efficacy. Industry research indicates that pharmaceutical executives recognize the potential impact of improving medication adherence on patient outcomes and company revenues. However, the lack of substantiated ROI data often prevents companies from implementing structured adherence programs.

Simple care medical services medication adherence program utilizes innovative software to identify patients at risk of non-adherence. Developed and executed by clinical pharmacists, interventions aim to address barriers to adherence. Clinical pharmacists leverage their comprehensive understanding of each patient's clinical profile, including drug interactions and disease considerations, to personalize interventions.

Simple Care Medical Services' programs are developed and implemented by clinical pharmacists—experts in medication therapy management and adherence.

Patient engagement remains the primary predictor of medication adherence and drives our programs. Experts estimate that medication non-adherence costs pharmaceutical companies more than $180 billion per year. Nearly half of all patients do not take medications as prescribed; more than 1 in 5 new prescriptions are never filled, and adherence is lowest among patients with chronic conditions.

Medication adherence, and its correlation with refill frequency, holds significant financial implications for pharmaceutical companies. According to the Network for Excellence in Health Innovation (NEHI), poor medication adherence contributes to 125,000 deaths in the United States annually.

Several factors contribute to patient non-adherence. Simple Care Medical Services' pharmacist-led patient education and disease-state management programs address each of these factors to improve patient adherence.

The Asheville Project, as reported in the Journal of the American Pharmacists Association, assessed the long-term clinical, economic, and humanistic impacts of pharmacist-led interventions on a cohort of 207 asthma patients. Patients who received pharmacist-led medication management demonstrated sustained improvements in asthma outcomes over a period of up to five years across subjective and objective measures. While spending on asthma medications increased, patients saved an average of $725 annually in direct costs and $1,230 in indirect costs.